Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D2RTQ0
|
|||
| Drug Name |
SB12
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Paroxysmal nocturnal haemoglobinuria [ICD-11: 3A21.0; ICD-10: D59.5] | Phase 3 | [1] | |
| Company |
Samsung Bioepis
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Complement C5 (CO5) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Complement and coagulation cascades | |||
| Prion diseases | ||||
| Pertussis | ||||
| Staphylococcus aureus infection | ||||
| Herpes simplex infection | ||||
| Systemic lupus erythematosus | ||||
| Reactome | Activation of C3 and C5 | |||
| Peptide ligand-binding receptors | ||||
| G alpha (i) signalling events | ||||
| Regulation of Complement cascade | ||||
| WikiPathways | Complement Activation, Classical Pathway | |||
| Human Complement System | ||||
| Spinal Cord Injury | ||||
| Allograft Rejection | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| Complement cascade | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04058158) A Study to Compare SB12 (Proposed Eculizumab Biosimilar) to Soliris in Subjects With Paroxysmal Nocturnal Haemoglobinuria. U.S. National Institutes of Health. | |||
| REF 2 | Clinical promise of next-generation complement therapeutics. Nat Rev Drug Discov. 2019 Sep;18(9):707-729. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.